Brevan Howard Capital Management’s Minerva Neurosciences NERV Stock Holding History

Brevan Howard Capital Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$172K	Buy	+28,629	New	+$164K	﹤0.01%	1933

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Brevan Howard Capital Management's NERV Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Minerva Neurosciences (NERV) in Q1 2026: 28,629 shares worth $172K. The stake represents ﹤0.01% of the portfolio and ranks #1933 among its holdings.

47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

Brevan Howard Capital Management held 28,629 shares of Minerva Neurosciences worth $172K as of Q1 2026.
Minerva Neurosciences was a new Brevan Howard Capital Management position in Q1 2026.
Minerva Neurosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1933 holding.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.